FDA Approves Qiagen’s PartoSure for Preterm Labor

On April 20, 2018, Qiagen announced the FDA approval of the novel test named PartoSureTM, used for assessing the risk of spontaneous preterm birth in patients with symptoms of preterm labor.

• Source: Ddu
• 637
• May 17, 2018